C

    CervoMed Inc. (CRVO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.63
    +0.03 (+1.15%)

    Market Cap: $39.31M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    26%(9/34)
    Avg Surprise
    -5922.65%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.57
    Range$-0.73 - $-0.44
    4 analysts
    EPS Revisions
    1
    0
    7d
    2
    2
    30d
    EPS Estimate Drift
    90d ago$-0.58-2.5%
    60d ago$-0.58-3.1%
    30d ago$-0.58-3.1%
    7d ago$-0.55+3.1%
    Current$-0.57
    Revenue Consensus
    $50000
    Range$0 - $300000
    6 analysts
    Dec 31, 2026
    EPS Consensus$0.02
    Range$-0.75 - $1.06
    5 analysts
    Revenue Consensus
    $-29170
    Range$-162500 - $637500
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.02---
    Sep 26EST
    		-$-0.57---
    Jun 26
    		$-0.64$-0.87+26.44%Beat+8.6%
    Mar 26
    		$-0.86$-0.79-8.46%Miss-53.6%
    Dec 25
    		$-0.88$-0.70-25.71%Miss-10.0%
    Sep 25
    		$-0.84$-0.64-31.25%Miss-52.7%
    Jun 25
    		$-0.70$-0.62-12.90%Miss-159.3%
    Mar 25
    		$-0.56$-0.62+10.16%Beat-36.6%
    Dec 24
    		$-0.80$-0.63-26.98%Miss-110.5%
    Sep 24
    		$-0.55$-0.41-34.15%Miss-184.6%
    Jun 24
    		$-0.27$-0.29+6.90%Beat+82.6%
    Mar 24
    		$-0.41$-0.32-28.13%Miss+79.6%
    Dec 23
    		$-0.38$-0.29-31.03%Miss+81.0%
    Sep 23
    		$0.65$-0.95+168.42%Beat+131.6%
    Jun 23
    		$-1.55$-2.90+46.42%Beat+49.7%
    Mar 23
    		$-2.01$-1.91-5.24%Miss+39.6%
    Dec 22
    		$-2.00$-2.22+9.91%Beat+11.1%
    Sep 22
    		$-2.06$-2.06+0.00%Beat+77.1%
    Jun 22
    		$-3.09$-2.04-51.47%Miss-3.0%
    Mar 22
    		$-3.33$-1.75-90.29%Miss+26.0%
    Dec 21
    		$-2.25$-0.04-5525.00%Miss+50.0%
    Sep 21
    		$-9.00$-0.04-22400.00%Miss-71.4%
    Jun 21
    		$-3.00$-0.04-6566.67%Miss+60.0%
    Mar 21
    		$-4.50$-0.04-9900.00%Miss+14.3%
    Dec 20
    		$-4.50$-0.06-8081.82%Miss-121.4%
    Sep 20
    		$-5.25$-0.06-9445.45%Miss+88.3%
    Jun 20
    		$-7.50$-0.06-12400.00%Miss+84.1%
    Mar 20
    		$-5.25$-0.09-5733.33%Miss+91.4%
    Dec 19
    		$21.00$-0.14+15100.00%Beat+116.9%
    Sep 19
    		$-45.00$-0.71-6238.03%Miss+69.2%
    Jun 19
    		$-47.25$-0.90-5150.00%Miss+16.0%
    Mar 19
    		$-60.75$-0.91-6575.82%Miss-16086.8%
    Dec 18
    		$-124.50$-1.28-9626.56%Miss-62350.0%
    Sep 18
    		$-146.25$-0.90-16150.00%Miss-26983.3%
    Jun 18
    		$-56.25$-0.06-93650.00%Miss-3078.0%
    Mar 18
    		$0.38$-0.04+1050.00%Beat-
    Sep 17
    		$0.20$0.00N/ABeat+102.5%
    Jun 17
    		$-0.54$0.00N/AMiss-
    Mar 17
    		$-1.77$0.00N/AMiss-
    Dec 16
    		$0.00$0.00N/ABeat-
    Sep 16
    		$-7.95$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.82EV/EBITDA1.64x
    Price/FCF-0.96xFCF Yield-103.84%
    Profitability
    Profit Margin0.00%Operating Margin-9407.00%
    ROE-107.60%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio8.57xQuick Ratio8.57x
    Trading Statistics
    Beta-4.31Avg Volume345.61K
    52-Week High$10.8952-Week Low$2.13

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.63
    SMA 20$2.74
    SMA 50$2.98
    SMA 200$4.74
    EMA 10$2.65
    EMA 20$2.71
    EMA 50$2.92
    EMA 200$4.28

    MACD

    Line: -0.08Signal: -0.09Hist: 0.00

    ADX

    ADX: 14.1+DI: 23.7-DI: 22.6

    Aroon & PSAR

    Aroon Up44.0
    Aroon Down12.0
    PSAR$2.90

    Bollinger Bands

    Upper Band$3.05
    Lower Band$2.43
    %B Position2268%(Upper)
    Band Width0.32

    RSI (14-Day)

    Neutral
    43.8

    Momentum Oscillators

    Stoch %K17.7
    Stoch %D19.1
    Williams %R-81.2
    ROC (10d)0.8%
    Momentum0.02
    CCI (20d)-74.9
    MFI (14d)32.9

    Volatility Measures

    ATR (14d)$0.19(7.2%)
    StdDev (20d)0.16
    Hist Vol61.5%(High)

    Volume Flow

    VWAP$2.61
    OBV427.4M
    AD Line-101.1M
    CMF (20d)0.007

    Volume Metrics

    Avg Vol (20d)356.8K
    Vol Ratio0.3x(Low)
    VWMA (20d)$2.77

    Pivot Points

    R3$2.78
    R2$2.73
    R1$2.66
    Pivot Point$2.61
    S1$2.54
    S2$2.49
    S3$2.42

    Advanced Oscillators

    TSI-12.45
    Ultimate Osc51.2
    KST-81.32

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$8,726$322,569$1.76M$1.92M$2.16M$1.94M$3.29M$2.35M$2.49M$1.53M
    Cost of Revenue$0$0N/A$0$0$0$7.09M$0$0$0$2.85M$0
    Gross Profit$0$0$8,726$322,569$1.76M$1.92M$2.16M$1.94M$3.29M$2.35M$2.49M$1.53M
    Operating Expenses$6.68M$8.11M$8.34M$8.37M$8.37M$7.22M$9.40M$7.34M$6.28M$4.94M$4.97M$4.20M
    R&D$4.32M$5.14M$5.83M$6.04M$5.11M$4.84M$7.09M$5.13M$3.77M$2.81M$2.86M$1.79M
    SG&A$2.36M$2.98M$2.51M$2.33M$3.27M$2.38M$2.32M$2.21M$2.51M$2.13M$2.12M$2.41M
    Operating Income$-6,678,551$-8,110,524$-8,331,519$-8,044,199$-6,616,275$-5,302,884$-7,240,821$-5,396,273$-2,995,099$-2,594,938$-2,480,450$-2,675,129
    Interest Income$104,897$147,387$240,938$318,787$368,127$408,985$532,181$646,172$678,441$80,633$118,652$47,667
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-6,571,656$-7,964,158$-8,087,290$-7,726,639$-6,258,404$-4,894,034$-6,705,914$-4,753,541$-2,316,905$-2,514,335$-2,362,398$2.15M
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-6,571,656$-7,964,158$-8,087,290$-7,726,639$-6,258,404$-4,894,034$-6,705,914$-4,753,541$-2,316,905$-2,514,335$-2,362,398$2.15M
    EBITDA$-6,695,692$-8,181,649$-8,474,286$-8,266,951$-6,861,197$-5,554,847$-7,621,094$-5,883,703$-2,995,346$-2,594,968$-2,481,050$2.10M
    EBIT$-6,676,553$-8,111,545$-8,328,228$-8,045,426$-6,626,531$-5,303,019$-7,238,095$-5,399,713$-2,995,346$-2,594,968$-2,481,050$2.10M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CRVO

    News

    Roth MKM Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $7

    Roth MKM has reiterated its Buy rating for CervoMed (CRVO.US) but has reduced the target price to $7. This adjustment reflects the firm's updated valuation for the company.

    Moomoo•8/21/26•
    Somewhat-Bearish

    ARMISTICE CAPITAL, LLC Acquires New Stake in CervoMed Inc (CRVO)

    Armistice Capital has acquired a new stake in CervoMed Inc (CRVO), purchasing 1,592,863 shares at $3.10 each, representing a 9.53% ownership in the clinical-stage biotechnology company. This strategic move aligns with Armistice Capital's focus on healthcare and biotechnology investments, despite CervoMed's current financial challenges and negative profitability metrics. The investment may signal a speculative bet on the success of CervoMed's lead product candidate, Neflamapimod, which targets age-related neurologic disorders.

    GuruFocus•8/20/26•
    Somewhat-Bearish

    CervoMed (CRVO): RA Capital discloses 8.6% stake through 1.27M warrant shares

    RA Capital Management and its affiliated funds have disclosed an 8.6% beneficial ownership stake in CervoMed Inc. (CRVO), primarily through warrants exercisable for 1,266,143 shares of common stock. This disclosure, based on a SCHEDULE 13G/A filing, indicates that RA Capital, along with Peter Kolchinsky and Rajeev Shah, collectively hold shared voting and dispositive power over these warrant shares. The percentage is calculated based on 13,526,233 outstanding shares plus the warrant shares, and RA Capital disclaims beneficial ownership for Section 13(d) purposes due to delegated voting and investment power.

    Stock Titan•8/14/26•
    Neutral

    CervoMed (CRVO) holders CVI and Heights report 0% stake in amended filing

    CVI Investments, Inc. and Heights Capital Management, Inc. have filed an amended Schedule 13G/A for CervoMed Inc. (CRVO), reporting a 0% beneficial ownership in the company. This filing indicates that both entities collectively hold no shares and possess no voting or dispositive power over CervoMed's common stock, confirming their ownership is 5% or less. Heights Capital Management acts as the investment manager for CVI Investments.

    Stock Titan•8/14/26•
    Neutral

    Armistice Capital discloses 9.53% CervoMed (CRVO) ownership via Master Fund

    Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.53% in CervoMed Inc. (CRVO), totaling 1,592,863 shares of common stock. These shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as the investment manager, granting them shared voting and dispositive power. The Master Fund disclaims beneficial ownership due to its investment management agreement.

    Stock Titan•8/14/26•
    Neutral

    Frequently Asked Questions About CRVO

    Does CRVO pay dividends?
    CervoMed Inc. (CRVO) does not currently pay a regular dividend.
    What is CRVO's market cap?
    CervoMed Inc. (CRVO) has a market capitalization of $39.31M with a current stock price of $2.63.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In